Reply to "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy".
作者信息
Coto-Hernández Rubén, Fábregas Ruano María Teresa
机构信息
Unidad de Gestión Clínica de Medicina Interna, Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Universitario Central de Asturias, Oviedo, Spain.
Medicina Interna, Hospital Universitario Puerta del Mar, Cádiz, Spain.
出版信息
J Thromb Haemost. 2020 Jun;18(6):1519-1520. doi: 10.1111/jth.14852. Epub 2020 May 6.
Abstract
摘要
相似文献
1
Reply to "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy".
J Thromb Haemost. 2020 Jun;18(6):1519-1520. doi: 10.1111/jth.14852. Epub 2020 May 6.
2
Response to 'Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy'.
J Thromb Haemost. 2020 Jun;18(6):1520-1521. doi: 10.1111/jth.14851. Epub 2020 May 6.
3
In Response to "Coagulopathy of Coronavirus Disease 2019".
Crit Care Med. 2020 Nov;48(11):e1159-e1160. doi: 10.1097/CCM.0000000000004545.
4
Thrombocytopenia and coagulation disorders due to COVID 19 infection with concomitant cardiovascular diseases requiring anti-platelet and anticoagulant therapy, which strategy?
Clin Chim Acta. 2020 Sep;508:109. doi: 10.1016/j.cca.2020.05.031. Epub 2020 May 14.
5
COVID-19-associated coagulopathy.
Diagnosis (Berl). 2020 Nov 18;7(4):357-363. doi: 10.1515/dx-2020-0078.
6
The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19.
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):262-264. doi: 10.1093/ehjcvp/pvaa048.
7
Focus on coronavirus disease 2019 associated coagulopathy.
Chin Med J (Engl). 2020 Sep 20;133(18):2239-2241. doi: 10.1097/CM9.0000000000001019.
8
More on COVID-19 coagulopathy in Caucasian patients.
Br J Haematol. 2020 Jun;189(6):1060-1061. doi: 10.1111/bjh.16791. Epub 2020 May 25.
9
COVID-19 update: Covid-19-associated coagulopathy.
J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3.
10
RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19.
J Thromb Haemost. 2020 Aug;18(8):2057-2058. doi: 10.1111/jth.14853. Epub 2020 Jul 15.
引用本文的文献
1
Management and Prevention of Cerebrovascular Accidents in SARS-CoV-2-Positive Patients Recovering from COVID-19: a Case Report and Review of Literature.
SN Compr Clin Med. 2021;3(1):279-290. doi: 10.1007/s42399-021-00744-3. Epub 2021 Jan 16.
2
COVID-19 - Toward a comprehensive understanding of the disease.
Cardiol J. 2020;27(2):99-114. doi: 10.5603/CJ.a2020.0065. Epub 2020 May 7.
本文引用的文献
1
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
2
Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.
Clin Chim Acta. 2020 Jul;506:145-148. doi: 10.1016/j.cca.2020.03.022. Epub 2020 Mar 13.
3
New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey.
BMJ Open. 2017 Sep 27;7(9):e017046. doi: 10.1136/bmjopen-2017-017046.
4
Disseminated intravascular coagulation.
Nat Rev Dis Primers. 2016 Jun 2;2:16037. doi: 10.1038/nrdp.2016.37.
Zotero 插件